uracil has been researched along with Apolipoprotein B-100, Familial Defective in 1 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hovingh, GK | 1 |
| Klausen, IC | 1 |
| Heggen, E | 1 |
| McCarty, K | 1 |
| Zhou, R | 1 |
| Isaac, BF | 1 |
| Taub, R | 1 |
| Langslet, G | 1 |
| Kastelein, JJP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia[NCT03038022] | Phase 2 | 116 participants (Actual) | Interventional | 2017-02-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for uracil and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia.
Topics: Heterozygote; Humans; Hyperlipoproteinemia Type II; Pyridazines; Uracil | 2022 |